<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444050</url>
  </required_header>
  <id_info>
    <org_study_id>CV023-005</org_study_id>
    <nct_id>NCT04444050</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986331 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, drug levels and drug
      effects of single and multiple oral doses of BMS-986331 versus placebo in healthy
      participants and healthy Japanese participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 76 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to 13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) leading to study discontinuation</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 46 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF</measure>
    <time_frame>Up to 46 days</time_frame>
    <description>QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS</measure>
    <time_frame>Up to 46 days</time_frame>
    <description>QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Up to 46 days</time_frame>
    <description>PR interval is the time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part 1 Single Ascending Dose (SAD): Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Panel 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Panel 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 SAD: Optional Split-dose Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Multiple Ascending Dose (MAD): Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 MAD: Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 MAD: Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 MAD: Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 MAD in Japanese Participants (J-MAD): Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 J-MAD: Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 J-MAD: Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 J-MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986331</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 SAD: Optional Split-dose Panel</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 2</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 3</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 4</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 5</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 6</arm_group_label>
    <arm_group_label>Part 1 Single Ascending Dose (SAD): Panel 1</arm_group_label>
    <arm_group_label>Part 2 MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 2</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 3</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 4</arm_group_label>
    <arm_group_label>Part 2 Multiple Ascending Dose (MAD): Panel 1</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Panel 2</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Panel 3</arm_group_label>
    <arm_group_label>Part 3 MAD in Japanese Participants (J-MAD): Panel 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Matching BMS-986331</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 SAD: Optional Split-dose Panel</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 2</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 3</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 4</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 5</arm_group_label>
    <arm_group_label>Part 1 SAD: Panel 6</arm_group_label>
    <arm_group_label>Part 1 Single Ascending Dose (SAD): Panel 1</arm_group_label>
    <arm_group_label>Part 2 MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 2</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 3</arm_group_label>
    <arm_group_label>Part 2 MAD: Panel 4</arm_group_label>
    <arm_group_label>Part 2 Multiple Ascending Dose (MAD): Panel 1</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Optional (to be determined) Panel</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Panel 2</arm_group_label>
    <arm_group_label>Part 3 J-MAD: Panel 3</arm_group_label>
    <arm_group_label>Part 3 MAD in Japanese Participants (J-MAD): Panel 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  No clinically significant deviations in medical history, physical examination, ECGs,
             vital signs, and clinical laboratory determinations

          -  A body mass index of 18 - 32 kg/m2, inclusive

          -  Women and men must agree to follow specific methods of contraception, if applicable

        For J-MAD Part 3

          -  Must be Japanese (both biological parents are ethnically Japanese)

        Exclusion Criteria:

          -  Women who are of childbearing potential

          -  Women who are pregnant or breastfeeding

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease that could impact upon the absorption of study drug

          -  Any surgery within 12 weeks of study drug administration

        Other protocol-defined inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Dickerson, Site 0002</last_name>
      <phone>913-410-2973</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

